MAP2K7 and neoplasm: In patients who do not respond to anti-EGFR therapy, MEK inhibitors are under investigation to target downstream effector pathways (RAS-RAF-MEK-MAPK) to limit proliferation and promote tumoural apoptosis to inhibit tumour growth [17].